1
|
Anticancer properties of indole derivatives as IsoCombretastatin A-4 analogues. Eur J Med Chem 2021; 223:113656. [PMID: 34171660 DOI: 10.1016/j.ejmech.2021.113656] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2021] [Revised: 06/14/2021] [Accepted: 06/14/2021] [Indexed: 12/19/2022]
Abstract
In this study, a variety of original ligands related to Combretastatin A-4 and isoCombretastatin A-4, able to inhibit the tubulin polymerization into microtubules, was designed, synthesized, and evaluated. Our lead compound 15d having a quinazoline as A-ring and a 2-substituted indole as B-ring separated by a N-methyl linker displayed a remarkable sub-nanomolar level of cytotoxicity (IC50 < 1 nM) against 9 human cancer cell lines.
Collapse
|
2
|
Álvarez R, Aramburu L, Gajate C, Vicente-Blázquez A, Mollinedo F, Medarde M, Peláez R. Methylsulfanylpyridine based diheteroaryl isocombretastatin analogs as potent anti-proliferative agents. Eur J Med Chem 2020; 209:112933. [PMID: 33328100 DOI: 10.1016/j.ejmech.2020.112933] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2020] [Revised: 09/30/2020] [Accepted: 10/08/2020] [Indexed: 01/30/2023]
Abstract
Isocombretastatins are the not isomerizable 1,1-diarylethene isomers of combretastatins. Both families of antimitotics are poorly soluble and new analogs with improved water solubility are needed. The ubiquitous 3,4,5-trimethoxyphenyl ring and most of its replacements contribute to the solubility problem. 39 new compounds belonging to two series of isocombretastatin analogs with 2-chloro-6-methylsulfanyl-4-pyridinyl or 2,6-bis(methylsulfanyl)-4-pyridinyl moieties replacing the 3,4,5-trimethoxyphenyl have been synthesized and their antimitotic activity and aqueous solubility have been studied. We show here that 2-chloro-6-methylsulfanylpyridines are more successful replacements than 2,6-bis(methylsulfanyl)pyridines, giving highly potent tubulin inhibitors and cytotoxic compounds with improved water solubilities. The optimal combination is with indole rings carrying polar substitutions at the three position. The resulting diheteroaryl isocombretastatin analogs showed potent cytotoxic activity against human cancer cell lines caused by tubulin inhibition, as shown by in vitro tubulin polymerization inhibitory assays, cell cycle analysis, and confocal microscopy studies. Cell cycle analysis also showed apoptotic responses following G2/M arrest after treatment. Conformational analysis and docking studies were applied to propose binding modes of the compounds at the colchicine site of tubulin and were in good agreement with the observed SAR. 2-Chloro-6-methylsulfanylpyridines represent a new and successful trimethoxyphenyl ring substitution for the development of improved colchicine site ligands.
Collapse
Affiliation(s)
- Raquel Álvarez
- Laboratorio de Química Orgánica y Farmacéutica, Departamento de Ciencias Farmacéuticas, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007, Salamanca, Spain; Instituto de Investigación Biomédica de Salamanca (IBSAL), Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007, Salamanca, Spain; Centro de Investigación de Enfermedades Tropicales de La Universidad de Salamanca (CIETUS). Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007, Salamanca, Spain.
| | - Laura Aramburu
- Laboratorio de Química Orgánica y Farmacéutica, Departamento de Ciencias Farmacéuticas, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007, Salamanca, Spain; Instituto de Investigación Biomédica de Salamanca (IBSAL), Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007, Salamanca, Spain; Centro de Investigación de Enfermedades Tropicales de La Universidad de Salamanca (CIETUS). Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007, Salamanca, Spain.
| | - Consuelo Gajate
- Laboratory of Cell Death and Cancer Therapy, Department of Molecular Biomedicine, Centro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas (CSIC), E-28040, Madrid, Spain.
| | - Alba Vicente-Blázquez
- Laboratorio de Química Orgánica y Farmacéutica, Departamento de Ciencias Farmacéuticas, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007, Salamanca, Spain; Laboratory of Cell Death and Cancer Therapy, Department of Molecular Biomedicine, Centro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas (CSIC), E-28040, Madrid, Spain; Instituto de Investigación Biomédica de Salamanca (IBSAL), Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007, Salamanca, Spain; Centro de Investigación de Enfermedades Tropicales de La Universidad de Salamanca (CIETUS). Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007, Salamanca, Spain.
| | - Faustino Mollinedo
- Laboratory of Cell Death and Cancer Therapy, Department of Molecular Biomedicine, Centro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas (CSIC), E-28040, Madrid, Spain.
| | - Manuel Medarde
- Laboratorio de Química Orgánica y Farmacéutica, Departamento de Ciencias Farmacéuticas, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007, Salamanca, Spain; Instituto de Investigación Biomédica de Salamanca (IBSAL), Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007, Salamanca, Spain; Centro de Investigación de Enfermedades Tropicales de La Universidad de Salamanca (CIETUS). Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007, Salamanca, Spain.
| | - Rafael Peláez
- Laboratorio de Química Orgánica y Farmacéutica, Departamento de Ciencias Farmacéuticas, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007, Salamanca, Spain; Instituto de Investigación Biomédica de Salamanca (IBSAL), Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007, Salamanca, Spain; Centro de Investigación de Enfermedades Tropicales de La Universidad de Salamanca (CIETUS). Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007, Salamanca, Spain.
| |
Collapse
|
3
|
Hamze A, Alami M, Provot O. Developments of isoCombretastatin A-4 derivatives as highly cytotoxic agents. Eur J Med Chem 2020; 190:112110. [PMID: 32061961 DOI: 10.1016/j.ejmech.2020.112110] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2019] [Revised: 01/29/2020] [Accepted: 01/29/2020] [Indexed: 10/25/2022]
Abstract
Combretastatin A-4 (CA-4) is a natural anti-cancer agent isolated in 1989 from the African willow tree, Combretum caffrum. Due to its chemical simplicity, this (Z)-stilbene has been the subject of many structural modifications mainly to improve its chemical and metabolic stability. Beside a large number of synthetic analogues, isoCombretastatin A-4 (isoCA-4), has proved to be a solution of choice since this non-natural isomer of CA-4 is stable, easier to synthesize and has equivalent antitumor properties as CA-4. In this review, we will present the structure-activity relationships (SARs) around isoCA-4 since its discovery in 2007. In a first part, we will describe some alternatives to replace the phenol B-ring of isoCA-4, then we will focus on the variations made on the 1,1-ethylene double bond and then, we will evocate very recent exiting results concerning the possible replacements of the 3,4,5-trimethoxyphenyl A-ring of isoCA-4 by suitable heterocycles.
Collapse
Affiliation(s)
- Abdallah Hamze
- Université Paris-Saclay, CNRS, BioCIS, 92290, Châtenay-Malabry, France
| | - Mouad Alami
- Université Paris-Saclay, CNRS, BioCIS, 92290, Châtenay-Malabry, France.
| | - Olivier Provot
- Université Paris-Saclay, CNRS, BioCIS, 92290, Châtenay-Malabry, France.
| |
Collapse
|
4
|
Abstract
The stilbenoid combretastatin and its derivatives are potent inhibitors of angiogenesis and cell proliferation and induce apoptosis. They disrupt cytoskeletal dynamics and modulate cell morphology, motility, and invasion. Hence they have been viewed as potential as anticancer agents. The impediments of poor solubility and bioavailability and the spontaneous geometric isomerisation of combretastatin into an inactive form have led to intensive efforts towards evolving novel analogues to provide more efficacious biological outcome. Importantly, isomerically stable and biologically active cis-restricted analogues have been synthesised and tested. However, very few analogues have been tested in preclinical models to assess their effects on processes relevant to cancer development and progression. Hence the accent here is on the signalling systems operated by the new derivatives and their biological effects with reference to cancer progression. Combretastatins modulate an extensive network of signalling emphasising their varied versatility. Harnessing these systems and accentuating or counteracting aberrant signalling could open potential avenues of approach to the designing of novel derivatives with enhanced performance. The import of mammalian target of rapamycin pathway, which co-ordinates growth factor receptor signalling, epithelial-mesenchymal transition activation and angiogenic signalling, is emphasised. It may be viewed as a prime target for allosteric inhibition in combination with combretastatin analogues to ascertain their potential in cancer control.
Collapse
Affiliation(s)
- Gajanan V Sherbet
- School of Engineering, University of Newcastle Upon Tyne, Newcastle Upon Tyne, UK.,The Institute for Molecular Medicine, Huntington Beach, California
| |
Collapse
|
5
|
Khelifi I, Naret T, Hamze A, Bignon J, Levaique H, Garcia Alvarez MC, Dubois J, Provot O, Alami M. N,N-bis-heteroaryl methylamines: Potent anti-mitotic and highly cytotoxic agents. Eur J Med Chem 2019; 168:176-188. [DOI: 10.1016/j.ejmech.2019.02.038] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2018] [Revised: 01/09/2019] [Accepted: 02/10/2019] [Indexed: 10/27/2022]
|
6
|
Naret T, Khelifi I, Provot O, Bignon J, Levaique H, Dubois J, Souce M, Kasselouri A, Deroussent A, Paci A, Varela PF, Gigant B, Alami M, Hamze A. 1,1-Diheterocyclic Ethylenes Derived from Quinaldine and Carbazole as New Tubulin-Polymerization Inhibitors: Synthesis, Metabolism, and Biological Evaluation. J Med Chem 2018; 62:1902-1916. [PMID: 30525602 DOI: 10.1021/acs.jmedchem.8b01386] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
We report the synthesis and metabolic and biological evaluation of a series of 17 novel heterocyclic derivatives of isocombretastatin-A4 (iso-CA-4) and their structure-activity relationships. Among these derivatives, the most active compound, 4f, inhibited the growth of a panel of seven cancer cell lines with an IC50 in the low nanomolar range. In addition, 4f showed interesting activity against CA-4-resistant colon-carcinoma cells and multidrug-resistant leukemia cells. It also induced G2/M cell-cycle arrest. Structural data indicated binding of 4f to the colchicine site of tubulin, likely preventing the curved-to-straight tubulin structural changes that occur during microtubule assembly. Also, 4f disrupted the blood-vessel-like assembly formed by human umbilical-vein endothelial cells in vitro, suggesting its function as a vascular-disrupting agent. An in vitro metabolism study of 4f showed its high human-microsomal stability in comparison with that of iso-CA-4. The physicochemical properties of 4f may be conducive to CNS permeability, suggesting that this compound may be a possible candidate for the treatment of glioblastoma.
Collapse
Affiliation(s)
- Timothée Naret
- BioCIS, Université Paris-Sud, CNRS, Équipe Labellisée Ligue Contre le Cancer , Université Paris-Saclay , F-92290 Châtenay-Malabry , France
| | - Ilhem Khelifi
- BioCIS, Université Paris-Sud, CNRS, Équipe Labellisée Ligue Contre le Cancer , Université Paris-Saclay , F-92290 Châtenay-Malabry , France
| | - Olivier Provot
- BioCIS, Université Paris-Sud, CNRS, Équipe Labellisée Ligue Contre le Cancer , Université Paris-Saclay , F-92290 Châtenay-Malabry , France
| | - Jérôme Bignon
- CIBI Plateform , Institut de Chimie des Substances Naturelles, UPR 2301, CNRS , F-91198 Gif sur Yvette , France
| | - Hélène Levaique
- CIBI Plateform , Institut de Chimie des Substances Naturelles, UPR 2301, CNRS , F-91198 Gif sur Yvette , France
| | - Joelle Dubois
- Institut de Chimie des Substances Naturelles, UPR 2301, CNRS , F-91198 Gif sur Yvette , France
| | - Martin Souce
- Lip(Sys)2, Chimie Analytique Pharmaceutique (FKA EA4041 Groupe de Chimie Analytique de Paris-Sud), Université Paris-Sud , Université Paris-Saclay , F-92290 Châtenay-Malabry , France
| | - Athena Kasselouri
- Lip(Sys)2, Chimie Analytique Pharmaceutique (FKA EA4041 Groupe de Chimie Analytique de Paris-Sud), Université Paris-Sud , Université Paris-Saclay , F-92290 Châtenay-Malabry , France
| | - Alain Deroussent
- UMR 8203, Laboratoire de Vectorologie et Thérapeutique Anticancéreuses, CNRS, Université Paris-Sud , Université Paris-Saclay, Gustave Roussy , F-94805 Villejuif , France
| | - Angélo Paci
- UMR 8203, Laboratoire de Vectorologie et Thérapeutique Anticancéreuses, CNRS, Université Paris-Sud , Université Paris-Saclay, Gustave Roussy , F-94805 Villejuif , France.,Department of Pharmacology and Drug Analysis, Gustave Roussy Cancer Campus Grand Paris , Université Paris-Sud , F-94805 Villejuif , France
| | - Paloma F Varela
- Institute for Integrative Biology of the Cell (I2BC), CEA, CNRS , Université Paris-Sud, Université Paris-Saclay , F-91198 Gif-sur-Yvette , France
| | - Benoît Gigant
- Institute for Integrative Biology of the Cell (I2BC), CEA, CNRS , Université Paris-Sud, Université Paris-Saclay , F-91198 Gif-sur-Yvette , France
| | - Mouad Alami
- BioCIS, Université Paris-Sud, CNRS, Équipe Labellisée Ligue Contre le Cancer , Université Paris-Saclay , F-92290 Châtenay-Malabry , France
| | - Abdallah Hamze
- BioCIS, Université Paris-Sud, CNRS, Équipe Labellisée Ligue Contre le Cancer , Université Paris-Saclay , F-92290 Châtenay-Malabry , France
| |
Collapse
|
7
|
Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site. Eur J Med Chem 2018; 163:428-442. [PMID: 30530194 DOI: 10.1016/j.ejmech.2018.11.070] [Citation(s) in RCA: 60] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2018] [Revised: 11/20/2018] [Accepted: 11/28/2018] [Indexed: 01/09/2023]
Abstract
A series of novel isocombretastatin A-4 (isoCA-4) analogs were designed and synthesized by replacing 3,4,5-trimethoylphenyl and isovanillin of isoCA-4 with quinoline and indole moieties, respectively. The structure activity relationships (SARs) of these synthesized quinoline-indole derivatives have been intensively investigated. Two compounds 27c and 34b exhibited the most potent activities against five cancer cell lines with IC50 values ranging from 2 to 11 nM, which were comparable to those of Combretastatin A-4 (CA-4, 1). Further mechanism investigations revealed that 34b effectively inhibited the microtubule polymerization by binding to the colchicine site of tubulin. Further cellular mechanism studies elucidated that 34b disrupted cell microtubule networks, arrested the cell cycle at G2/M phase, induced apoptosis and depolarized mitochondria of K562 cells. Moreover, 34b displayed potent anti-vascular activity in both wound healing and tube formation assays. Importantly, 27c and 34b significantly inhibited tumor growth in H22 xenograft models without apparent toxicity, suggesting that 27c and 34b deserve further research as potent antitumor agents for cancer therapy.
Collapse
|
8
|
Pang Y, An B, Lou L, Zhang J, Yan J, Huang L, Li X, Yin S. Design, Synthesis, and Biological Evaluation of Novel Selenium-Containing Isocombretastatins and Phenstatins as Antitumor Agents. J Med Chem 2017; 60:7300-7314. [DOI: 10.1021/acs.jmedchem.7b00480] [Citation(s) in RCA: 93] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- Yanqing Pang
- School of Pharmaceutical
Sciences, Sun Yat-sen University, Guangzhou 510006, China
| | - Baijiao An
- School of Pharmaceutical
Sciences, Sun Yat-sen University, Guangzhou 510006, China
| | - Lanlan Lou
- School of Pharmaceutical
Sciences, Sun Yat-sen University, Guangzhou 510006, China
| | - Junsheng Zhang
- School of Pharmaceutical
Sciences, Sun Yat-sen University, Guangzhou 510006, China
| | - Jun Yan
- School of Pharmaceutical
Sciences, Sun Yat-sen University, Guangzhou 510006, China
| | - Ling Huang
- School of Pharmaceutical
Sciences, Sun Yat-sen University, Guangzhou 510006, China
| | - Xingshu Li
- School of Pharmaceutical
Sciences, Sun Yat-sen University, Guangzhou 510006, China
| | - Sheng Yin
- School of Pharmaceutical
Sciences, Sun Yat-sen University, Guangzhou 510006, China
| |
Collapse
|
9
|
Khelifi I, Naret T, Renko D, Hamze A, Bernadat G, Bignon J, Lenoir C, Dubois J, Brion JD, Provot O, Alami M. Design, synthesis and anticancer properties of IsoCombretaQuinolines as potent tubulin assembly inhibitors. Eur J Med Chem 2016; 127:1025-1034. [PMID: 28166995 DOI: 10.1016/j.ejmech.2016.11.012] [Citation(s) in RCA: 63] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2016] [Revised: 10/26/2016] [Accepted: 11/05/2016] [Indexed: 10/20/2022]
Abstract
The synthesis and evaluation of a new series of IsoCombretaQuinolines (IsoCoQuines) 2 with a 2-substituted-quinoline in place of the 3,4,5-trimethoxyphenyl ring present in isoCA-4 and CA-4 are described. Most of these compounds displayed a potent cytotoxic activity (IC50 < 10 nM) against a panel of five human cancer cell lines and inhibited tubulin assembly at a micromolar level. The most potent analogue 2b, having a 3-hydroxy-4-methoxyphenyl as B-ring, led to cell cycle arrest in G2/M phase. Docking studies indicate that 2b showed a binding mode comparable to those previously observed with quinazoline analogous (IsoCoQ) and with isoCA-4 at the colchicine binding site of tubulin.
Collapse
Affiliation(s)
- Ilhem Khelifi
- BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay, 92290, Châtenay-Malabry, France
| | - Timothée Naret
- BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay, 92290, Châtenay-Malabry, France
| | - Dolor Renko
- BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay, 92290, Châtenay-Malabry, France
| | - Abdallah Hamze
- BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay, 92290, Châtenay-Malabry, France
| | - Guillaume Bernadat
- BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay, 92290, Châtenay-Malabry, France
| | - Jérome Bignon
- Institut de Chimie des Substances Naturelles, UPR 2301, CNRS Avenue de La Terrasse, F-91198 Gif sur Yvette, France
| | - Christine Lenoir
- Institut de Chimie des Substances Naturelles, UPR 2301, CNRS Avenue de La Terrasse, F-91198 Gif sur Yvette, France
| | - Joëlle Dubois
- Institut de Chimie des Substances Naturelles, UPR 2301, CNRS Avenue de La Terrasse, F-91198 Gif sur Yvette, France
| | - Jean-Daniel Brion
- BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay, 92290, Châtenay-Malabry, France
| | - Olivier Provot
- BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay, 92290, Châtenay-Malabry, France.
| | - Mouad Alami
- BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay, 92290, Châtenay-Malabry, France.
| |
Collapse
|
10
|
Soussi MA, Provot O, Bernadat G, Bignon J, Wdzieczak-Bakala J, Desravines D, Dubois J, Brion JD, Messaoudi S, Alami M. Discovery of azaisoerianin derivatives as potential antitumors agents. Eur J Med Chem 2014; 78:178-89. [DOI: 10.1016/j.ejmech.2014.03.032] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2014] [Revised: 03/11/2014] [Accepted: 03/12/2014] [Indexed: 01/05/2023]
|
11
|
Aprile S, Zaninetti R, Del Grosso E, Genazzani AA, Grosa G. Metabolic fate of combretastatin A-1: LC-DAD-MS/MS investigation and biological evaluation of its reactive metabolites. J Pharm Biomed Anal 2013; 78-79:233-42. [DOI: 10.1016/j.jpba.2013.02.030] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2012] [Revised: 02/18/2013] [Accepted: 02/20/2013] [Indexed: 11/17/2022]
|
12
|
Rasolofonjatovo E, Provot O, Hamze A, Rodrigo J, Bignon J, Wdzieczak-Bakala J, Lenoir C, Desravines D, Dubois J, Brion JD, Alami M. Design, synthesis and anticancer properties of 5-arylbenzoxepins as conformationally restricted iso combretastatin A-4 analogs. Eur J Med Chem 2013; 62:28-39. [DOI: 10.1016/j.ejmech.2012.12.042] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2012] [Revised: 12/18/2012] [Accepted: 12/23/2012] [Indexed: 11/29/2022]
|
13
|
Rasolofonjatovo E, Provot O, Hamze A, Rodrigo J, Bignon J, Wdzieczak-Bakala J, Desravines D, Dubois J, Brion JD, Alami M. Conformationnally restricted naphthalene derivatives type isocombretastatin A-4 and isoerianin analogues: Synthesis, cytotoxicity and antitubulin activity. Eur J Med Chem 2012; 52:22-32. [DOI: 10.1016/j.ejmech.2012.03.001] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2012] [Revised: 02/28/2012] [Accepted: 03/01/2012] [Indexed: 11/29/2022]
|
14
|
Rasolofonjatovo E, Tréguier B, Provot O, Hamze A, Brion JD, Alami M. A One-Pot Three-Step Synthesis of Z-Trisubstituted Olefins from Arylalkynes and Their Cyclization into 4-Aryl-2H-chromenes. European J Org Chem 2012. [DOI: 10.1002/ejoc.201101735] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|